Accelerating Cell Therapy: Navigating Immune Mediation with Comprehensive Cell Interaction Screening6 Nov 20256 Nov 2025White Papers
A Configurable, Cross-Modality Extracellular Vesicle Standard (EV-CMS) Enables Quantitative Evaluation Across Nanotechnology Platforms6 Nov 20256 Nov 2025Posters
Selective Programming Drives Faster Expansion of Antigen-Specific T cells to Improve Cell Therapy Manufacturing and Outcomes6 Nov 20256 Nov 2025Posters
High Throughput Screening of a Programmable Cellular Interface (sbPCI) Rapidly Identifies Configurations Capable of Expanding T Cell Subsets Without Isolation6 Nov 20256 Nov 2025Posters
StimulusBio CEO Presents at TLSF 2024: Non-Dilutive Funding for Life Science Companies7 Nov 202415 Sep 2025Events
Positioning our Affiliate, Van Heron Labs, as a Premier New Player in Cell and Gene Therapy12 Jun 202428 Jun 2024Case Studies
